Clin2
NCT07524816Likely a fitRecruiting

CAR-T Cell Therapy for Relapsed Lymphoma

Large B-Cell Lymphoma (LBCL)

Treatments studied

Part of Cancer clinical trials.

This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
76 people
Ages
18 years to 80 years
Study type
Observational

Who can take part

  • You are 18 years or older
  • Your lymphoma has come back after treatment or no longer responds to treatment (relapsed or refractory)
  • Your cancer cells express CD19 (a protein doctors can identify through a biopsy)
  • You have received at least one prior cancer treatment
  • You are not pregnant and do not have active hepatitis B, hepatitis C, or HIV
  • You have an adequate number of healthy immune cells (specifically a certain type called naïve T-lymphocytes)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07447726Not yet recruiting· Phase 1/Phase 2
CAR-T cell therapy for relapsed/refractory large B-cell lymphoma

This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.

NCT07539688Not yet recruiting· Phase 1
CAR-T Cell Therapy for Resistant B-Cell Lymphoma

This trial tests CY-219, a type of cell therapy that trains your immune cells to fight B-cell lymphoma that has come back or stopped responding to standard treatments. The study evaluates whether this approach is safe and effective for patients like you.

NCT06698484Recruiting· Phase 2
CAR-T cell therapy for B-cell lymphoma that has returned or not responded

This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.

Bandar Tun Razak, Kuala Lumpur
NCT06647329Not yet recruiting· Phase 1
CAR-T cell therapy for relapsed blood cancers

This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.

Zhengzhou, Henan
NCT06378190Recruiting· Phase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma

This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.

Barcelona, Barcelona
NCT06479356Recruiting· Phase 2
CAR T-cell therapy for relapsed large B-cell lymphoma

This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.

Tianjin, Tianjin Municipality

Hear when a new Large B-Cell Lymphoma (LBCL) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.